Chinese vaccine company Sinovac aims for 600 million dose capacity for COVID-19

By: |
Updated: Dec 07, 2020 5:46 PM

China has at least five COVID-19 vaccine candidates running late stage clinical trials across more than a dozen countries.

Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 per cent stake in Sinovac for an investment of USD 500 million.Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 per cent stake in Sinovac for an investment of USD 500 million.

Chinese vaccine company Sinovac announced Monday that it is planning to complete a new facility to double its annual vaccine production capacity to 600 million doses by the end of the year, while also securing a USD 500 million investment in a boost to its COVID-19 vaccine development efforts.

The company is currently conducting the last stage of clinical trials for its vaccine candidate in Brazil, Turkey and Indonesia and is among the frontrunners of China’ s vaccine efforts.

China has at least five COVID-19 vaccine candidates running late stage clinical trials across more than a dozen countries.

Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 per cent stake in Sinovac for an investment of USD 500 million.

The funds will allow the company to “improve our vaccine sales capabilities, expand in Asia markets, develop and access new technologies, and most importantly, accelerate our efforts to help combat the global pandemic,” Sinovac CEO Yin Weidong said in a statement.

On Sunday, 1.2 million doses of its experimental vaccine arrived in Indonesia and are expected to be approved for use soon.

Sinovac’s candidate is a two-dose inactivated vaccine, an old-school technology in which a live virus is killed and then purified.

It can be stored at 2 to 8 C (36 to 46 F), within the range of a normal refrigerator, unlike some other vaccines candidates that require far lower temperatures.

Sinovac’s experimental vaccine is currently approved for emergency use in China, although it has not yet obtained final market approval.

Under emergency use, it has been distributed to groups the Chinese government deemed suitable, including front-line medical workers and border personnel.

The latest public data from the company, published in the science journal Lancet, showed its candidate produced lower levels of antibodies in people than those who have recovered from COVID-19.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Health worker dies days after jab; official says no vaccine link
2India undertaking contractual supplies of coronavirus vaccines to several countries: MEA
3India will be role model on how to vaccinate billion people at scale, in trusted manner: Nandan Nilekani